ClinicalTrials.Veeva

Menu

Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia

V

Visus Therapeutics

Status and phase

Completed
Phase 3

Conditions

Presbyopia

Treatments

Drug: Vehicle
Drug: BRIMOCHOL™ PF
Drug: Carbachol PF

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia

Full description

Multicenter, Double-Masked, Randomized, Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF Topical Ophthalmic Solution With Emmetropic Phakic and Pseudophakic Presbyopia

Enrollment

629 patients

Sex

All

Ages

45 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Male or female in good general health
  • Must have presbyopia

Exclusion criteria

  • History of allergic reaction to the study drug or any of its components
  • Any disease or medical condition that, in the opinion of the Investigator, would prevent the subject from participating in the study or might confound study results

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

629 participants in 3 patient groups, including a placebo group

BRIMOCHOL™ PF
Experimental group
Description:
A single drop in each eye at a visit.
Treatment:
Drug: BRIMOCHOL™ PF
Carbachol PF
Active Comparator group
Description:
A single drop in each eye at a visit.
Treatment:
Drug: Carbachol PF
Vehicle
Placebo Comparator group
Description:
A single drop in each eye at a visit.
Treatment:
Drug: Vehicle

Trial contacts and locations

42

Loading...

Central trial contact

David Le

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems